Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of topical cyclosporine ophthalmic solution 0.05% (Restasis, Allergan) on the signs and symptoms of dry eye in patients undergoing LASIK or photorefractive keratectomy (PRK).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Innovative Medical
• Treatments: Cyclosporine; Cyclosporins

Criteria

Inclusion Criteria:

• Males or females > 18 years old

• Mild-moderate symptoms of dry eye prior to surgery

• Scheduled to undergo bilateral LASIK or PRK

• Likely to complete all study visits and able to provide informed consent

Exclusion Criteria:

• Prior use of topical cyclosporine within the last 1 year

• Known contraindications to any study medication or ingredients

• Female of child bearing potential not using reliable methods of birth control, or pregnant or lactating females.

• Ocular disorders

• Active ocular diseases or uncontrolled systemic disease

• Active ocular allergies